- DKK101.26bn
- DKK126.40bn
- $3.72bn
Brief: Genmab Gets FDA Breakthrough Therapy Designation For Rinatabart Sesutecan
Europe Research Roundup: Airbus, BBVA, Domino's Pizza
Brief: Genmab Says Phase 3 EPCORE FL-1 Clinical Trial Met Dual Primary Endpoints In Patients With R/R FL
Brief: Genmab H1 Operating Profit Rises To $548 Mln
Brief: Genmab Says 2025 Revised FY Revenue Outlook 3,500 USD Million To 3,700 USD Million
Genmab rises after blood cancer drug meets main goal of late-stage study
Brief: Genmab Announces Phase 3 Epcore Clinical Trial Results
Brief: Genmab Says Net Sales Of Darzalex In Q2 $3,539 Mln
Europe Research Roundup: Aegon, AXA, Sonova Holding
Europe Research Roundup: Heidelberg Materials, Krones, Mondi
Brief: Genmab Says Revenue Was $715 Million For First Three Months Of 2025
Brief: Genmab To Submit SBLA To FDA For Epcoritamab Plus Rituximab And Lenalidomide
Brief: Genmab Says To Submit SBLA To FDA For Ecoritamab In 2025
Europe Research Roundup: Antofagasta, Fraport, Man Group
Brief: Genmab Announces Q1 Nets Sales Of Darzalex
Brief: TIVDAK® (Tisotumab Vedotin) Approved By Japan Ministry Of Health, Labour And Welfare For Treatment Of Advanced Or Recurrent Cervical Cancer That Has Progressed On Or After Chemotherapy
Brief: Genmab Announces Repurchase Of Up To 2.2 Million Shares With A Maximum Aggregate Total Value Of Dkk 4 Billion
Brief: Genmab To Vigorously Defend Alleged Claims Of Trade Secret Misappropriation By Abbvie Inc.
Brief: Genmab Says Investigational Rinatabart Sesutecan (Rina-S) Continues To Show Encouraging Antitumor Activity